Abstract

EMERGING TREATMENT AND PREVENSION AGAINST NOVEL CORONA VIRUS (COVID-19): A REVIEW

Shubham Gore*, Rahul Mohan, Asawari Kunde and Pooja Patil

ABSTRACT

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit admission. Currently, supportive care is the standard treatment for COVID-19. The two pharmacologic therapies shown to have clinical benefit in prospective randomized trials are remdesivir and dexamethasone. Several clinical trials are ongoing to help determine the efficacy of various other treatments, including antiviral therapies, repurposed medications, and antiinflammatory medications. Because of the unknown benefit and limited medication availability, these medications should be used in consultation with an infectious diseases specialist and on a case-by-case basis. There are currently over 169 COVID-19 vaccine candidates under development, with 26 of these in the human trial phase. In this review article we had focused on currently used pharmaceutical supportive treatment against novel corona virus disease (COVID-19).

Keywords: .